Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
1 evidence topic · 3 sources
Summary
The evidence documents heterogeneous resistance mutations within and between lesions in progressing GIST. Treatment-associated symptom burden also persists: severe fatigue occurred in 30% of participants with GIST and 33% of those receiving a TKI in the cited fatigue study. These findings address resistance and treatment burden rather than demonstrating comparative efficacy between individual TKIs.